The stock of Amylyx Pharmaceuticals Inc (AMLX) has gone up by 6.81% for the week, with a 9.08% rise in the past month and a 13.30% rise in the past quarter. The volatility ratio for the week is 5.03%, and the volatility levels for the past 30 days are 7.85% for AMLX. The simple moving average for the past 20 days is 4.36% for AMLX’s stock, with a -77.01% simple moving average for the past 200 days.
Is It Worth Investing in Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Right Now?
Additionally, the 36-month beta value for AMLX is -0.64. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AMLX is 45.97M and currently, short sellers hold a 8.22% ratio of that float. The average trading volume of AMLX on July 31, 2024 was 1.77M shares.
AMLX) stock’s latest price update
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)’s stock price has soared by 7.37 in relation to previous closing price of 1.91. Nevertheless, the company has seen a gain of 6.81% in its stock price over the last five trading days. prnewswire.com reported 2024-07-18 that NEW YORK , July 18, 2024 /PRNewswire/ — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Amylyx insiders caused the company to misrepresent or fail to disclose that (i) RELYVRIO’s commercial prospects were overstated; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, RELYVRIO’s prescription rate was also overstated; (v) insiders attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO’s prescription data; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Analysts’ Opinion of AMLX
Many brokerage firms have already submitted their reports for AMLX stocks, with Mizuho repeating the rating for AMLX by listing it as a “Neutral.” The predicted price for AMLX in the upcoming period, according to Mizuho is $4 based on the research report published on March 18, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see AMLX reach a price target of $4, previously predicting the price at $37. The rating they have provided for AMLX stocks is “Neutral” according to the report published on March 11th, 2024.
Leerink Partners gave a rating of “Market Perform” to AMLX, setting the target price at $4 in the report published on March 11th of the current year.
AMLX Trading at 11.40% from the 50-Day Moving Average
After a stumble in the market that brought AMLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.35% of loss for the given period.
Volatility was left at 7.85%, however, over the last 30 days, the volatility rate increased by 5.03%, as shares surge +18.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.30% upper at present.
During the last 5 trading sessions, AMLX rose by +7.03%, which changed the moving average for the period of 200-days by -88.33% in comparison to the 20-day moving average, which settled at $1.9807. In addition, Amylyx Pharmaceuticals Inc saw -86.07% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMLX starting from Quimi Daphne, who purchase 2,250 shares at the price of $1.89 back on May 15 ’24. After this action, Quimi Daphne now owns 5,000 shares of Amylyx Pharmaceuticals Inc, valued at $4,252 using the latest closing price.
Mazzariello Gina, the Chief Legal Officer of Amylyx Pharmaceuticals Inc, sale 10,455 shares at $1.88 during a trade that took place back on May 15 ’24, which means that Mazzariello Gina is holding 151,477 shares at $19,654 based on the most recent closing price.
Stock Fundamentals for AMLX
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.66 for the gross margin
The net margin for Amylyx Pharmaceuticals Inc stands at -0.18. The total capital return value is set at -0.25. Equity return is now at value -21.00, with -17.23 for asset returns.
Based on Amylyx Pharmaceuticals Inc (AMLX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 4.47. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -23.52.
Currently, EBITDA for the company is 39.89 million with net debt to EBITDA at 2.08. When we switch over and look at the enterprise to sales, we see a ratio of -0.06. The receivables turnover for the company is 19.27for trailing twelve months and the total asset turnover is 0.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.48.
Conclusion
In conclusion, Amylyx Pharmaceuticals Inc (AMLX) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
